Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR TKI-responsive, advanced non-small cell lung cancer (NSCLC) that subsequently progresses.
B. Halmos
Research Funding - OSI Pharmaceuticals
P. Fu
No relevant relationships to disclose
N. A. Pennell
Consultant or Advisory Role - Boehringer Ingelheim
Research Funding - Genentech
G. A. Otterson
Consultant or Advisory Role - Celgene; Genentech
Research Funding - Celgene; Genentech; Pfizer; Tragara Pharmaceuticals
T. Mekhail
Consultant or Advisory Role - Genentech
Honoraria - Genentech; Lilly
M. R. Snell
No relevant relationships to disclose
J. P. Kuebler
No relevant relationships to disclose
S. M. Gadgeel
Consultant or Advisory Role - Genentech; OSI Pharmaceuticals
Honoraria - Genentech; OSI Pharmaceuticals
A. Conrad
No relevant relationships to disclose
A. T. Stefanski
Employment or Leadership Position - OSI Pharmaceuticals
Stock Ownership - OSI Pharmaceuticals
A. Dowlati
Research Funding - OSI Pharmaceuticals